Calogero Crapanzano
ASPAG, CSM Licata, Licata, Italy
Andrea Politano
Clinica S. Croce, Orselina, Switzerland
Chiara Amendola
ASST Lariana, Como, Italy
Despoina Koukouna
U.O. Psichiatrica MANTOVA 1, MANTOVA, Italy
Ilaria Casolaro
ASST Lariana, Como, Italy
Abstract:
Vortioxetine is a multimodal antidepressant that binds with high affinity the serotonin transporter (SERT) > (serotonin receptor) 5-HT3 > 5-HT1A > 5-HT7 > 5-HT1B > 5-HT1D. It acts by inhibiting the SERT, with antagonism activity on the 5-HT1D, 5-HT7 and 5-HT3 receptors, partial agonism activity on the 5-HT1B receptor, agonism activity at 5HT1A receptor1. Vortioxetine is a compound approved by the FDA for major depressive disorder. Its efficacy and tolerability are widely proven. Regarding tolerability, both in short and long-term studies, nausea was the most common treatment emergent adverse event (TEAE) and the primary TEAE that caused discontinuation after vortioxetine treatment.
Keywords:Vortioxetine ,multimodal antidepressant ,treatment emergent adverse event (TEAE)